These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33827675)

  • 81. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.
    Förster S; Buschert VC; Buchholz HG; Teipel SJ; Friese U; Zach C; la Fougere C; Rominger A; Drzezga A; Hampel H; Bartenstein P; Buerger K
    J Alzheimers Dis; 2011; 25(4):695-706. PubMed ID: 21498904
    [TBL] [Abstract][Full Text] [Related]  

  • 84. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.
    Haense C; Buerger K; Kalbe E; Drzezga A; Teipel SJ; Markiewicz P; Herholz K; Heiss WD; Hampel H
    Eur J Neurol; 2008 Nov; 15(11):1155-62. PubMed ID: 18803648
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease-like hypometabolism.
    Chiba Y; Fujishiro H; Ota K; Kasanuki K; Arai H; Hirayasu Y; Sato K; Iseki E
    Int J Geriatr Psychiatry; 2015 Mar; 30(3):316-23. PubMed ID: 24839913
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
    Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
    J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Unravelling neural correlates of empathy deficits in Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.
    Giacomucci G; Galdo G; Polito C; Berti V; Padiglioni S; Mazzeo S; Chiaro E; De Cristofaro MT; Bagnoli S; Nacmias B; Sorbi S; Bessi V
    Behav Brain Res; 2022 Jun; 428():113893. PubMed ID: 35429513
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.
    Gilman S; Koeppe RA; Little R; An H; Junck L; Giordani B; Persad C; Heumann M; Wernette K
    Exp Neurol; 2005 Feb; 191 Suppl 1():S95-S103. PubMed ID: 15629765
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints.
    Picco A; Polidori MC; Ferrara M; Cecchetti R; Arnaldi D; Baglioni M; Morbelli S; Bastiani P; Bossert I; Fiorucci G; Brugnolo A; Dottorini ME; Nobili F; Mecocci P
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):764-75. PubMed ID: 24297504
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Characteristics of mild cognitive impairment tending to convert into Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a memory clinic.
    Kondo D; Ota K; Kasanuki K; Fujishiro H; Chiba Y; Murayama N; Sato K; Hirayasu Y; Arai H; Iseki E
    J Neurol Sci; 2016 Oct; 369():102-108. PubMed ID: 27653873
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tau positron emission tomography using [
    Kang JM; Lee SY; Seo S; Jeong HJ; Woo SH; Lee H; Lee YB; Yeon BK; Shin DH; Park KH; Kang H; Okamura N; Furumoto S; Yanai K; Villemagne VL; Seong JK; Na DL; Ido T; Cho J; Lee KM; Noh Y
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD).
    Scheef L; Grothe MJ; Koppara A; Daamen M; Boecker H; Biersack H; Schild HH; Wagner M; Teipel S; Jessen F
    Neuroimage Clin; 2019; 21():101612. PubMed ID: 30555006
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2.
    Yildirim Z; Delen F; Berron D; Baumeister H; Ziegler G; Schütze H; Glanz W; Dobisch L; Peters O; Freiesleben SD; Schneider LS; Priller J; Spruth EJ; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Meiberth D; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Laske C; Munk MH; Spottke A; Roy N; Heneka M; Brosseron F; Wagner M; Roeske S; Ramirez A; Ewers M; Dechent P; Hetzer S; Scheffler K; Kleineidam L; Wolfsgruber S; Yakupov R; Schmid M; Berger M; Gurvit H; Jessen F; Duzel E
    Alzheimers Res Ther; 2023 Feb; 15(1):43. PubMed ID: 36855049
    [TBL] [Abstract][Full Text] [Related]  

  • 96. High-resolution NMR metabolomics of patients with subjective cognitive decline plus: Perturbations in the metabolism of glucose and branched-chain amino acids.
    Yang Z; Wang J; Chen J; Luo M; Xie Q; Rong Y; Wu Y; Cao Z; Liu Y
    Neurobiol Dis; 2022 Sep; 171():105782. PubMed ID: 35680005
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Langbaum JB; Chen K; Lee W; Reschke C; Bandy D; Fleisher AS; Alexander GE; Foster NL; Weiner MW; Koeppe RA; Jagust WJ; Reiman EM;
    Neuroimage; 2009 May; 45(4):1107-16. PubMed ID: 19349228
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta.
    Li Q; Pan FF; Huang Q; Lo CZ; Xie F; Guo Q
    Front Aging Neurosci; 2022; 14():1046445. PubMed ID: 36389070
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Neural correlates and predictors of subjective cognitive decline in patients with Parkinson's disease.
    Ophey A; Krohm F; Kalbe E; Greuel A; Drzezga A; Tittgemeyer M; Timmermann L; Jessen F; Eggers C; Maier F
    Neurol Sci; 2022 May; 43(5):3153-3163. PubMed ID: 34820745
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE.
    Yu X; Shi R; Zhou X; Zhang M; Cai Y; Jiang J; Han Y
    Alzheimers Dement; 2024 Jul; ():. PubMed ID: 38982860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.